Abstract:Background and objective: The association between human intestinal microbes and disease is an emerging topic in microbiome research, with potential implications in cancer diagnosis. Meanwhile, immune checkpoint inhibitor (ICI) therapy has been extensively applied to cancer patients but with relatively low overall response rate owing to pathological complexity. Thus, accurate prediction of cancer onset as well as patients' response to ICI treatment through non-invasive methods, such as gut microbiome profiling, could greatly facilitate cancer diagnosis and treatment practice, which essentially improves patients' quality of life. With the rapid accumulation of microbiome sequencing data and advanced machine learning algorithms, the use of gut microbiome as predictive biomarkers presents a feasible approach to address these problems. Methods and results: The first model we built is a predictive model for classifying healthy people from patients with colon cancer (CRC). The data (originated from Curated Metagenomics Data of Human Microbiome) consists of 166 fecal samples from healthy population and equal number of CRC patients from two studies (PRJEB24748, PRJEB6070). The data were divided into training and testing sets with a 3:1 ratio. Using the training dataset, we developed a Gradient Boosting Decision Tree model. To demonstrate the model's generalizability, we evaluated it using the testing dataset and the model achieved an AUC score of 0.93 (accuracy: 89%). Moreover, using an external independent cohort (which included 52 CRC patients from PRJEB12449 and 52 healthy individuals), we obtained an AUC score of 0.94 (accuracy: 88%). We also detected bacteria highly related to CRC pathology including Solobacterium_moorei, which could be potential biomarkers for CRC diagnosis. In addition, to predict CRC patients' response to ICI, we built a random forest model based on patients' fecal microbiome data before the ICI treatment. In total, stool metagenomics data from 63 CRC patients were used, including 30 patients responding to ICI treatment and 33 non-responders. With five-fold cross-validation, we achieved training and testing AUC score of 0.89 and 0.72, respectively. With an external data with 11 CRC patients' samples, the classifier achieved an AUC of 0.78. Several microbial taxa were listed as important features contributing to the classification, e.g. Eubacterium hallii – a butyrate producer, which previously report to have a positive association with ICI clinical benefits. Conclusion: Using the non-invasive human gut microbiome data and advanced machine learning techniques, we present here two models with great performance to predict the occurrence of CRC and clinical response to ICI treatment in CRC patients. Similar strategy could be readily transferred to other cancer types to improve early diagnosis and patient stratification. Moreover, the microbial taxa identified to be essential features in the model could be developed as potential therapeutic targets. Citation Format: Die Dai, Xiaomin Xu, Wei Shen, Zhengnong Zhu, Fang Li, Xiaochen Yin, Yan Kou. Gut microbiome as a promising biomarker for colorectal cancer diagnosis and immunotherapy response prediction [abstract]. In: Proceedings of the AACR Special Conference on Colorectal Cancer; 2022 Oct 1-4; Portland, OR. Philadelphia (PA): AACR; Cancer Res 2022;82(23 Suppl_1) nr A030.

Metagenomics Biomarkers Selected for Prediction of Three Different Diseases in Chinese Population

Identification of potential biomarkers with colorectal cancer based on bioinformatics analysis and machine learning

Faecal microbiome-based machine learning for multi-class disease diagnosis

736 - Microbiota Metabolites Short-Chain Fatty Acids Inhibit TH1 Cell Induction of Colitis Through Promoting IL-10 Production Via GPR43

Taxonomic and functional profiling of fecal metagenomes for the early detection of colorectal cancer

Establishment and evaluation of prediction model for multiple disease classification based on gut microbial data

Gut metagenome-derived image augmentation and deep learning improve prediction accuracy of metabolic disease classification

Application of machine learning tools: Potential and useful approach for the prediction of type 2 diabetes mellitus based on the gut microbiome profile

Multimodal deep learning applied to classify healthy and disease states of human microbiome

Predicting the role of the human gut microbiome in type 1 diabetes using machine-learning methods

Identification of Microbial Markers Across Populations in Early Detection of Colorectal Cancer

A Machine Learning Framework of Functional Biomarker Discovery for Different Microbial Communities Based on Metagenomic Data.

Predicting the Role of the Human Gut Microbiome in Constipation Using Machine-Learning Methods: A Meta-Analysis

Comprehensive assessment of machine learning methods for diagnosing gastrointestinal diseases through whole metagenome sequencing data

Multi-label Learning for the Diagnosis of Cancer and Identification of Novel Biomarkers with High-throughput Omics

Toward Multilabel Classification for Multiple Disease Prediction Using Gut Microbiota Profiles

Microbial genes outperform species and SNVs as diagnostic markers for Crohn's disease on multicohort fecal metagenomes empowered by artificial intelligence

Human disease prediction from microbiome data by multiple feature fusion and deep learning

Abstract A030: Gut microbiome as a promising biomarker for colorectal cancer diagnosis and immunotherapy response prediction

Systematic Evaluation of Supervised Classifiers for Fecal Microbiota-Based Prediction of Colorectal Cancer

A multiple-dimension model for microbiota of patients with colorectal cancer from normal participants and other intestinal disorders